SBRA stock forecast, quote, news & analysis

Key Takeaways

• Sabra Health Care REIT (SBRA) surged approximately 14.8% in the last 30 days, climbing from $19.52 on June 29 to $22.40 as of July 27, 2026.
• The primary catalyst was a sweeping July 21 business update announcing the re-tenanting of 26 Avamere properties, with annualized cash rent expected to rise nearly 30% to $53 million.
• Sabra also settled its $300 million RCA mortgage for $200 million in cash, reducing leverage and lowering behavioral health concentration from 13% to 9% of annualized cash NOI.
• Full-year 2026 guidance was raised, with normalized FFO now projected at $1.53–$1.55 per share and normalized AFFO at $1.59–$1.61.
• Analyst sentiment turned increasingly positive, with Truist upgrading SBRA to Buy and subsequently raising its price target to $24 following the business update.
• Over the broader quarter, SBRA recovered from a June low of $17.67 to post a quarterly gain of approximately 10.4%, driven by improving fundamentals and strategic portfolio repositioning.

Sabra Health Care REIT (SBRA) Company Overview and Market Position

Sabra Health Care REIT, Inc. is a self-administered, self-managed real estate investment trust that owns and invests in healthcare real estate across the United States and Canada. The company's diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, and life science properties. Sabra structures long-term, triple-net lease agreements with healthcare operators, generating stable rental income while allowing tenants to focus on patient care and operational excellence. With a market capitalization of approximately $5.64 billion, Sabra is a prominent player in the healthcare REIT sector, and its high institutional ownership of 99.40% underscores its appeal among professional investors. The stock also offers a quarterly dividend of $0.30 per share, translating to an annualized yield above 5%.

Sabra Health Care REIT (SBRA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, SBRA delivered a robust gain of approximately 14.8%, advancing from a closing price of $19.52 on June 29 to $22.40 by July 27. The rally was heavily concentrated around July 21, when shares jumped more than 10% in a single session following the company's business update. Prior to that catalyst, the stock had been trading in a relatively tight range between $19.50 and $20.20 throughout early-to-mid July.

Zooming out to the full quarter, SBRA's trajectory was more volatile. From a starting point near $20.29 in late April, the stock faced significant downward pressure in late May and early June, bottoming at $17.67 on June 4 amid broader REIT sector weakness and uncertainty surrounding tenant performance. The stock then staged a steady recovery through the remainder of June and July, culminating in the post-announcement surge. The quarterly gain from late April to late July stands at approximately 10.4%, reflecting a clear V-shaped recovery driven by company-specific catalysts.

What Drove SBRA Stock Price in the Last 30 Days

The standout driver of SBRA's 30-day rally was the July 21 business update, which delivered several positive developments simultaneously. First, Sabra announced letters of intent to re-tenant all 26 properties previously leased to Avamere. Under the proposed transition, 22 properties would move to subsidiaries of Cascadia Healthcare, a respected operator concentrated in the Pacific Northwest, while the remaining four would transition to an existing Sabra tenant. The combined annualized cash rent for the portfolio is expected to reach $53 million — a nearly 30% increase over the $41 million collected from Avamere in the trailing twelve months.

Second, Sabra resolved the outstanding Recovery Centers of America mortgage, accepting a $200 million cash repayment to fully satisfy the $300 million obligation. The proceeds were used to reduce Sabra's revolving credit line, bringing pro forma Net Debt to EBITDA down from 5.0x to 4.8x and lowering behavioral health exposure. Third, the company announced additional portfolio initiatives — including lease amendments and rent resets — expected to add over $9 million in annualized cash NOI.

These developments led management to raise full-year 2026 guidance, with normalized FFO now forecast at $1.53–$1.55 per share and normalized AFFO at $1.59–$1.61. Analyst reactions were swift and favorable: Truist raised its price target from $22 to $24 and reiterated its Buy rating on July 22, while the broader consensus rating for SBRA stands at Moderate Buy with an average price target of $22.25. The company also announced that its Q2 2026 earnings would be released on August 3, further focusing investor attention on near-term results.

What Drove SBRA Stock Performance Over the Last Quarter

SBRA's quarterly performance tells a story of resilience and strategic execution. The stock entered the period trading near $20.29 and encountered significant headwinds in late May and early June, driven largely by macro-level pressure on REITs and healthcare property sectors. Shares fell to a quarterly low of $17.67 on June 4, reflecting investor concerns about operator health and interest rate sensitivity.

The recovery that followed was underpinned by several factors. First-quarter 2026 results, reported in late April, showed revenue of $211.74 million — a 20.9% year-over-year increase — and EPS of $0.16, meeting consensus estimates. Throughout June, institutional accumulation remained strong, with major holders such as Principal Financial Group, Norges Bank, and Brookfield Corp ON maintaining or expanding their positions. The July 8 Truist upgrade to Buy, which cited projected 7.8% average annual normalized FFO growth from 2026 through 2031, further supported sentiment. The quarter's defining moment, however, was the July 21 business update, which transformed the narrative from cautious recovery to proactive value creation and set the stage for SBRA's push toward its 52-week high of $22.55.

Trending AI Robots

Investors seeking to complement their own research with data-driven trading strategies may find value in Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that actively trade thousands of tickers across a wide spectrum of strategies, timeframes, and risk profiles. The Trending AI Robots section curates only the top-performing and most relevant bots, giving traders visibility into those currently demonstrating the strongest signals and performance metrics. Each bot is built on a distinct algorithmic approach — ranging from short-term pattern recognition to longer-horizon fundamental models — so users can explore options aligned with their individual trading style. Browsing this curated selection can help traders identify data-driven opportunities and stay informed about evolving market conditions.

SBRA Stock Forecast Drivers: What Investors Should Watch Next

The most immediate event on SBRA's calendar is the release of second-quarter 2026 earnings on August 3, followed by a conference call on August 4. Investors will closely scrutinize management's commentary on the Avamere-to-Cascadia transition timeline, any updates on the smaller portfolio initiatives, and whether early Q3 operating trends support the raised full-year guidance. The pace and execution of the re-tenanting process carries both upside potential and transition risk — smooth operator handovers could further boost confidence, while delays or unexpected costs could temper enthusiasm.

Beyond the near term, interest rate policy remains a critical macro factor for the entire REIT sector. Lower rates would likely support SBRA's valuation and reduce financing costs, while a higher-for-longer environment could pressure cap rates and acquisition economics. Additionally, the aging U.S. population continues to provide a structural tailwind for senior housing and skilled nursing demand, and Sabra's pivot toward increasing its managed senior housing concentration positions it to capture that demographic trend. Competitive dynamics among healthcare operators, regulatory changes affecting skilled nursing reimbursement, and the pace of institutional capital flows into healthcare real estate will also shape SBRA's trajectory through the remainder of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations